Search Results - Andreas Katopodis

  • Showing 1 - 1 results of 1
Refine Results
  1. 1
    ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy

    ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy by Christoph Huber, Christian Stocker, Patrizia Murer, Ulisse Salazar, Nicole Egli, Laetitia Petersen, Pia Neubert, Alexander Rau, Andreas Katopodis, Anais Zurbach, Dario Reichenstein

    Published 2025-07-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: